NASDAQ:CUE

Cue Biopharma Competitors

$11.50

-0.78 (-6.35 %)

(As of 04/12/2021 12:00 AM ET)

Add

Compare

Today's Range

$11.26

Now: $11.50▼

$12.26

50-Day Range

$11.20

MA: $13.22▼

$15.85

52-Week Range

$10.75

Now: $11.50▼

$31.69

Volume266,291 shs

Average Volume305,827 shs

Market Capitalization$350.26 million

P/E RatioN/A

Dividend YieldN/A

Beta1.95

Cue Biopharma (NASDAQ:CUE) Vs. CMPS, ZEAL, PMVP, KROS, ARQT, and TBPH

Should you be buying CUE stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Cue Biopharma, including COMPASS Pathways (CMPS), Zealand Pharma A/S (ZEAL), PMV Pharmaceuticals (PMVP), Keros Therapeutics (KROS), Arcutis Biotherapeutics (ARQT), and Theravance Biopharma (TBPH).

Cue Biopharma vs. COMPASS Pathways Stock

Cue Biopharma (NASDAQ:CUE) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, earnings and institutional ownership.

Valuation and Earnings

This table compares Cue Biopharma and COMPASS Pathways' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$3.46 million	101.23	$-36,700,000.00	($1.66)	-6.93
COMPASS Pathways	N/A	N/A	$-19,610,000.00	N/A	N/A

COMPASS Pathways has lower revenue, but higher earnings than Cue Biopharma.

Analyst Recommendations

This is a breakdown of recent recommendations for Cue Biopharma and COMPASS Pathways, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	0	0	4	0	3.00
COMPASS Pathways	0	0	6	0	3.00

Cue Biopharma currently has a consensus price target of $31.25, indicating a potential upside of 171.74%. COMPASS Pathways has a consensus price target of $70.75, indicating a potential upside of 85.26%. Given Cue Biopharma's higher possible upside, equities analysts plainly believe Cue Biopharma is more favorable than COMPASS Pathways.

Profitability

This table compares Cue Biopharma and COMPASS Pathways' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-1,142.70%	-63.69%	-50.08%
COMPASS Pathways	N/A	N/A	N/A

Institutional & Insider Ownership

64.5% of Cue Biopharma shares are held by institutional investors. Comparatively, 15.8% of COMPASS Pathways shares are held by institutional investors. 9.5% of Cue Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

COMPASS Pathways beats Cue Biopharma on 5 of the 9 factors compared between the two stocks.

Cue Biopharma vs. Zealand Pharma A/S Stock

Cue Biopharma (NASDAQ:CUE) and Zealand Pharma A/S (NASDAQ:ZEAL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Earnings & Valuation

This table compares Cue Biopharma and Zealand Pharma A/S's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$3.46 million	101.23	$-36,700,000.00	($1.66)	-6.93
Zealand Pharma A/S	$6.20 million	224.63	$-85,670,000.00	($2.54)	-12.63

Cue Biopharma has higher earnings, but lower revenue than Zealand Pharma A/S. Zealand Pharma A/S is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Cue Biopharma and Zealand Pharma A/S, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	0	0	4	0	3.00
Zealand Pharma A/S	0	0	2	0	3.00

Cue Biopharma presently has a consensus price target of $31.25, suggesting a potential upside of 171.74%. Zealand Pharma A/S has a consensus price target of $43.00, suggesting a potential upside of 34.00%. Given Cue Biopharma's higher probable upside, research analysts plainly believe Cue Biopharma is more favorable than Zealand Pharma A/S.

Profitability

This table compares Cue Biopharma and Zealand Pharma A/S's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-1,142.70%	-63.69%	-50.08%
Zealand Pharma A/S	-214.31%	-38.34%	-30.40%

Volatility & Risk

Cue Biopharma has a beta of 1.95, meaning that its stock price is 95% more volatile than the S&P 500. Comparatively, Zealand Pharma A/S has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.

Insider and Institutional Ownership

64.5% of Cue Biopharma shares are owned by institutional investors. Comparatively, 4.3% of Zealand Pharma A/S shares are owned by institutional investors. 9.5% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Cue Biopharma beats Zealand Pharma A/S on 8 of the 13 factors compared between the two stocks.

Cue Biopharma vs. PMV Pharmaceuticals Stock

Cue Biopharma (NASDAQ:CUE) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Earnings & Valuation

This table compares Cue Biopharma and PMV Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$3.46 million	101.23	$-36,700,000.00	($1.66)	-6.93
PMV Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

PMV Pharmaceuticals has lower revenue, but higher earnings than Cue Biopharma.

Insider and Institutional Ownership

64.5% of Cue Biopharma shares are owned by institutional investors. Comparatively, 69.7% of PMV Pharmaceuticals shares are owned by institutional investors. 9.5% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Cue Biopharma and PMV Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-1,142.70%	-63.69%	-50.08%
PMV Pharmaceuticals	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and price targets for Cue Biopharma and PMV Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	0	0	4	0	3.00
PMV Pharmaceuticals	0	1	3	0	2.75

Cue Biopharma presently has a consensus price target of $31.25, suggesting a potential upside of 171.74%. PMV Pharmaceuticals has a consensus price target of $38.00, suggesting a potential upside of 22.27%. Given Cue Biopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Cue Biopharma is more favorable than PMV Pharmaceuticals.

Summary

Cue Biopharma beats PMV Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Cue Biopharma vs. Keros Therapeutics Stock

Cue Biopharma (NASDAQ:CUE) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Earnings and Valuation

This table compares Cue Biopharma and Keros Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$3.46 million	101.23	$-36,700,000.00	($1.66)	-6.93
Keros Therapeutics	N/A	N/A	N/A	N/A	N/A

Keros Therapeutics has lower revenue, but higher earnings than Cue Biopharma.

Insider & Institutional Ownership

64.5% of Cue Biopharma shares are held by institutional investors. Comparatively, 58.4% of Keros Therapeutics shares are held by institutional investors. 9.5% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Cue Biopharma and Keros Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-1,142.70%	-63.69%	-50.08%
Keros Therapeutics	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cue Biopharma and Keros Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	0	0	4	0	3.00
Keros Therapeutics	0	0	4	0	3.00

Cue Biopharma presently has a consensus price target of $31.25, suggesting a potential upside of 171.74%. Keros Therapeutics has a consensus price target of $78.00, suggesting a potential upside of 32.90%. Given Cue Biopharma's higher probable upside, analysts clearly believe Cue Biopharma is more favorable than Keros Therapeutics.

Summary

Cue Biopharma beats Keros Therapeutics on 4 of the 7 factors compared between the two stocks.

Cue Biopharma vs. Arcutis Biotherapeutics Stock

Cue Biopharma (NASDAQ:CUE) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Earnings and Valuation

This table compares Cue Biopharma and Arcutis Biotherapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$3.46 million	101.23	$-36,700,000.00	($1.66)	-6.93
Arcutis Biotherapeutics	N/A	N/A	$-42,000,000.00	($22.78)	-1.19

Cue Biopharma has higher revenue and earnings than Arcutis Biotherapeutics. Cue Biopharma is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

64.5% of Cue Biopharma shares are held by institutional investors. Comparatively, 79.6% of Arcutis Biotherapeutics shares are held by institutional investors. 9.5% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Cue Biopharma and Arcutis Biotherapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-1,142.70%	-63.69%	-50.08%
Arcutis Biotherapeutics	N/A	-81.74%	-57.72%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cue Biopharma and Arcutis Biotherapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	0	0	4	0	3.00
Arcutis Biotherapeutics	0	0	4	0	3.00

Cue Biopharma presently has a consensus price target of $31.25, suggesting a potential upside of 171.74%. Arcutis Biotherapeutics has a consensus price target of $54.6667, suggesting a potential upside of 101.72%. Given Cue Biopharma's higher probable upside, analysts clearly believe Cue Biopharma is more favorable than Arcutis Biotherapeutics.

Summary

Cue Biopharma beats Arcutis Biotherapeutics on 7 of the 10 factors compared between the two stocks.

Cue Biopharma vs. Theravance Biopharma Stock

Cue Biopharma (NASDAQ:CUE) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Earnings and Valuation

This table compares Cue Biopharma and Theravance Biopharma's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$3.46 million	101.23	$-36,700,000.00	($1.66)	-6.93
Theravance Biopharma	$73.41 million	18.26	$-236,460,000.00	($4.25)	-4.84

Cue Biopharma has higher earnings, but lower revenue than Theravance Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

64.5% of Cue Biopharma shares are held by institutional investors. Comparatively, 80.4% of Theravance Biopharma shares are held by institutional investors. 9.5% of Cue Biopharma shares are held by insiders. Comparatively, 5.9% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Cue Biopharma and Theravance Biopharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-1,142.70%	-63.69%	-50.08%
Theravance Biopharma	-345.16%	N/A	-51.60%

Risk and Volatility

Cue Biopharma has a beta of 1.95, meaning that its stock price is 95% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cue Biopharma and Theravance Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	0	0	4	0	3.00
Theravance Biopharma	0	0	7	0	3.00

Cue Biopharma presently has a consensus price target of $31.25, suggesting a potential upside of 171.74%. Theravance Biopharma has a consensus price target of $33.2857, suggesting a potential upside of 61.97%. Given Cue Biopharma's higher probable upside, analysts clearly believe Cue Biopharma is more favorable than Theravance Biopharma.

Summary

Cue Biopharma beats Theravance Biopharma on 7 of the 13 factors compared between the two stocks.